title: Prognostic value of the six-minute walk in advanced non-small cell lung cancer.
abstract: BACKGROUND
  The 6 minute walk (6MW) is usually used to evaluate exercise capacity in a variety of patient populations. We hypothesized that the 6MW would decline after chemotherapy and assessed the prognostic value of this test.
  
  
  METHODS
  The 6MW was conducted in newly diagnosed advanced non-small cell lung cancer patients on three different days: twice before (one initial and one prechemotherapy test) and once after two cycles of chemotherapy.
  
  
  RESULTS
  Sixty-four patients were enrolled and 45 (70%) completed the study. For patients who dropped out the distance on initial 6MW was 361 m (SD 99) compared with 445 m (SD 85) for completers (p = 0.004).In the 45 completers, the mean 6MW decreased significantly after two cycles. There was a clinically significant (>54 m) decline in 6MW in 13 patients (29%), and an improved/unchanged 6MW in 32 patients (71%).For patients who walked <400 m on initial 6MW, rates of drop out were significantly higher (p = 0.02), progression of disease was statistically more frequent (p = 0.03), and median survival was significantly shorter: 6.7 months (95% confidence interval 2.6-10.8) compared with 13.9 months (95% confidence interval 10.0-17.8) in patients walking > or =400 m (p = 0.01).An initial 6MW of > or =400 m was the only variable with a significant effect on survival in a Cox regression after adjusting for all known covariates of interest.
  
  
  CONCLUSIONS
  The 6MW declines significantly after two cycles of chemotherapy. This decline may have been even greater as patients with lower 6MW were more likely to drop out of the study. An initial 6MW > or =400 m might be a useful prognostic factor for survival in patients with advanced non-small cell lung cancer.
authors.affiliation: Division of Pulmonary Diseases, Department of Internal Medicine, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada. gkasymja@pne.jgh.mcgill.ca
authors.forename: Goulnar
authors.initials: G
authors.lastname: Kasymjanova
authors.forename: José A
authors.initials: JA
authors.lastname: Correa
authors.forename: Harvey
authors.initials: H
authors.lastname: Kreisman
authors.forename: Esther
authors.initials: E
authors.lastname: Dajczman
authors.forename: Carmela
authors.initials: C
authors.lastname: Pepe
authors.forename: Sarah
authors.initials: S
authors.lastname: Dobson
authors.forename: Lucie
authors.initials: L
authors.lastname: Lajeunesse
authors.forename: Rajesh
authors.initials: R
authors.lastname: Sharma
authors.forename: David
authors.initials: D
authors.lastname: Small
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000503:physiopathology* / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000503:physiopathology* / Q000556:secondary; D005080:Exercise Test; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011788:Quality of Life; D012129:Respiratory Function Tests; D015996:Survival Rate; D013997:Time Factors; D014797:Vital Capacity; D016138:Walking / Q000502:physiology*